MREO Fundamental Analysis - MEREO BIOPHARMA GROUP PL-ADR

Name: MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock
Brand: MEREO BIOPHARMA GROUP PL-ADR
Rating: 5.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to MREO. MREO was compared to 534 industry peers in the Biotechnology industry. While MREO has a great health rating, there are worries on its profitability. MREO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MREO has reported negative net income.

MREO had a negative operating cash flow in the past year.

MREO had negative earnings in 4 of the past 5 years.

In the past 5 years MREO always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -79.29%, MREO is not doing good in the industry: 67.79% of the companies in the same industry are doing better.

With a Return On Equity value of -91.67%, MREO perfoms like the industry average, outperforming 47.94% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-79.29%
ROE	-91.67%
ROIC	N/A

ROA(3y)-46.82%

ROA(5y)-74.73%

ROE(3y)-61.85%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MREO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, MREO has more shares outstanding

The number of shares outstanding for MREO has been increased compared to 5 years ago.

Compared to 1 year ago, MREO has a worse debt to assets ratio.

2.2 Solvency

MREO has an Altman-Z score of 10.30. This indicates that MREO is financially healthy and has little risk of bankruptcy at the moment.

MREO has a Altman-Z score of 10.30. This is amongst the best in the industry. MREO outperforms 82.77% of its industry peers.

There is no outstanding debt for MREO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	10.3

ROIC/WACCN/A

WACC9.26%

2.3 Liquidity

MREO has a Current Ratio of 8.13. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 8.13, MREO is doing good in the industry, outperforming 73.97% of the companies in the same industry.

MREO has a Quick Ratio of 8.13. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.

MREO has a better Quick ratio (8.13) than 74.34% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.13
Quick Ratio	8.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MREO have decreased strongly by -50.00% in the last year.

MREO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

EPS 1Y (TTM)-50%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MREO will show a very strong growth in Earnings Per Share. The EPS will grow by 30.75% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-9.51%

EPS Next 2Y4.92%

EPS Next 3Y30.66%

EPS Next 5Y30.75%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MREO. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MREO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MREO's earnings are expected to grow with 30.66% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y4.92%

EPS Next 3Y30.66%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MREO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEREO BIOPHARMA GROUP PL-ADR

NASDAQ:MREO (10/24/2025, 8:00:01 PM)

After market: 2.06 +0.06 (+3%)

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-12 2025-08-12/bmo

Earnings (Next)11-10 2025-11-10

Inst Owners63.08%

Inst Owner Change0%

Ins Owners0.86%

Ins Owner Change0%

Market Cap318.00M

Revenue(TTM)500.00K

Net Income(TTM)-49663000

Analysts88

Price Target7.14 (257%)

Short Float %39.01%

Short Ratio9.79

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-873.16%

Min EPS beat(2)-1246.69%

Max EPS beat(2)-499.63%

EPS beat(4)0

Avg EPS beat(4)-611.5%

Min EPS beat(4)-1246.69%

Max EPS beat(4)-240.11%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-2%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-55.85%

EPS NY rev (1m)0%

EPS NY rev (3m)-18.39%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.39%

Revenue NY rev (1m)0%

Revenue NY rev (3m)21.55%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	636
P/FCF	N/A
P/OCF	N/A
P/B	5.87
P/tB	5.92
EV/EBITDA	N/A

EPS(TTM)-0.35

EYN/A

EPS(NY)-0.05

Fwd EYN/A

FCF(TTM)-0.21

FCFYN/A

OCF(TTM)-0.21

OCFYN/A

SpS0

BVpS0.34

TBVpS0.34

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-79.29%
ROE	-91.67%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-46.82%

ROA(5y)-74.73%

ROE(3y)-61.85%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	37.21%
Cap/Sales	64%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.13
Quick Ratio	8.13
Altman-Z	10.3

F-Score3

WACC9.26%

ROIC/WACCN/A

Cap/Depr(3y)35.04%

Cap/Depr(5y)37.89%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-50%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

EPS Next Y-9.51%

EPS Next 2Y4.92%

EPS Next 3Y30.66%

EPS Next 5Y30.75%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-66.68%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year56.93%

EBIT Next 3Y38.29%

EBIT Next 5YN/A

FCF growth 1Y16.45%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y17.26%

OCF growth 3YN/A

OCF growth 5YN/A

MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ

What is the ChartMill fundamental rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MREO.

What is the valuation status for MREO stock?

ChartMill assigns a valuation rating of 1 / 10 to MEREO BIOPHARMA GROUP PL-ADR (MREO). This can be considered as Overvalued.

Can you provide the profitability details for MEREO BIOPHARMA GROUP PL-ADR?

MEREO BIOPHARMA GROUP PL-ADR (MREO) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for MREO stock?

The Earnings per Share (EPS) of MEREO BIOPHARMA GROUP PL-ADR (MREO) is expected to decline by -9.51% in the next year.

MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ

What is the ChartMill fundamental rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

What is the valuation status for MREO stock?

Can you provide the profitability details for MEREO BIOPHARMA GROUP PL-ADR?

Can you provide the expected EPS growth for MREO stock?